|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Longitudinal patterns of N-terminal pro B-type natriuretic peptide, troponin T, and C-reactive protein in relation to the dynamics of echocardiographic parameters in heart failure patients.
|
31596459 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Were performed quality of life (Minnesota Living with Heart Failure Questionnaire-MLHFQ) and sleep questionnaires (Epworth, Pittsburgh Sleep Quality Index-PSQI), serum B-type natriuretic peptide (BNP), serum C-reactive protein, transthoracic echocardiography, cardiopulmonary exercise test and overnight polysomnography immediately before and six months after pericardiectomy.
|
31603935 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gold-nanorod enhances dielectric voltammetry detection of c-reactive protein: A predictive strategy for cardiac failure.
|
30716591 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Women had a lower risk for HF than men.Sex differences were seen for systolic blood pressure, heart rate, CRP, and NT-proBNP, with a lower HF risk in women.
|
30819375 |
2019 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our meta-analysis suggests that iron therapy can reduce heart failure hospitalization, increase cardiac function, improve quality of life, and decrease serum levels of NT-proBNP and CRP in patients with heart failure.
|
30853478 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, temporal changes in CRP levels were associated with cancer death in the overall cohort; HF patients with CRP ≥ 2.0 mg/L at both baseline and 1-year had significantly increased cancer death, while those with CRP ≥ 2.0 mg/L at baseline and < 2.0 mg/L at 1-year not.
|
31104823 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We undertook metabolomic and lipidomic phenotyping of a cohort of heart failure (HF) patients and utilized Multiple Regression Analysis (MRA) to identify associations to CPET and HFBio test performance (peak oxygen consumption (Peak VO2), oxygen uptake efficiency slope (OUES), exercise duration, and minute ventilation-carbon dioxide production slope (VE/VCO2 slope), as well as the established HF biomarkers of inflammation C-reactive protein (CRP), beta-galactoside-binding protein (galectin-3), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP)).
|
31220103 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficient electron-mediated electrochemical biosensor of gold wire for the rapid detection of C-reactive protein: A predictive strategy for heart failure.
|
31400725 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After multivariable adjustment for clinical variables and renal and CV biomarkers (estimated glomerular filtration rate, cystatin-C, urine albumin-to-creatinine ratio, FGF-23, high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein), low Klotho concentration remained strongly associated with increased risk of CV death or hospitalization for heart failure [adjusted hazard ratio (HR) 2.62; 95% confidence interval (CI) 1.35-5.08; P < 0.01].
|
30773798 |
2019 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Other predictors included ischemic etiology (HR 1.33, p=0.023), prior hospitalization for heart failure (HR 1.34, p=0.017), C-reactive protein (HR 1.04, p<0.001), and statin use (HR 0.70, p=0.016).
|
29169753 |
2018 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After beta-blocker treatment, hs-CRP levels are associated with functional capacity in HF patients.
|
29396658 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the multivariable analysis, the independent predictors of death were age (odds ratio (OR) 1.07, 95% confidence interval (CI) 1.02-1.13), C-reactive protein (CRP) at hospital admission (OR 1.12, 95% CI 1.04-1.21), length of the vegetation at diagnosis (OR 1.15, 95% CI 1.03-1.28), development of heart failure (OR 6.43, 95% CI 2.14-19.33), and embolic events during antimicrobial therapy (OR 12.14, 95% CI 2.11-71.89).
|
29382606 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After multivariable adjustment for baseline clinical characteristics and established biomarkers (high-sensitivity troponin I, brain-type natriuretic peptide, and high-sensitivity C-reactive protein), FGF-23 concentration in the top quartile was independently associated with an increased risk of CV death or heart failure hospitalization (adjusted hazard ratio [HR], 2.35; 95% CI, 1.82-3.02; P < .001) and its individual components.
|
29710336 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Older age, atrial fibrillation, hypertension, obesity, edema, high C-reactive protein, and smoking were risk factors for HF.
|
29934374 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the multivariable analysis, higher vWF concentrations (middle tertile hazard ratio [HR] 4.59, 95% confidence interval [CI] 1.55-13.50 [P=0.006]; upper tertile HR 4.10, 95% CI 1.43-11.75 [P=0.009]), age≥75years (HR 5.02, 95% CI 1.53-16.49; P=0.008), heart failure (HR 2.05, 1.01-4.19; P=0.048), C-reactive protein, log<sub>2</sub> per unit increase (HR 1.29, 95% CI 1.04-1.61; P=0.021), no warfarin at discharge (HR 4.96, 95% CI 2.02-12.20; P<0.0001) and no aspirin at discharge (HR 4.41, 95% CI 1.71-11.97; P=0.002) were independently associated with an increased risk of stroke and all-cause death, whereas female sex was a protective factor (HR 0.35, 0.16-0.78; P=0.01).
|
29685722 |
2018 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results hint towards an association of less common CRP genetic variants with increased mortality risk, depressive symptoms and peripheral CRP levels in this population of HF patients thereby suggesting a possible role of the inflammatory system as link between poor prognosis in HF and depressive symptoms.
|
29627531 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
As a result, previous studies have not provided conclusive evidence of the prognostic value of CRP for post-infarct LVSD or HF.
|
29633232 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
High CLA% was associated with significantly reduced risk of HF after adjustment for HF risk factors and C-reactive protein (hazard ratio [95% confidence interval], 0.64 [0.43-0.96]; quartile 4 versus quartile 1).
|
29306896 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk.
|
30427997 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the predictive value of single and repeated measurements of GDF-15 compared to Cystatin C and CRP for incidence of heart failure (HF) and death due to coronary heart disease (CHD) in the general population.
|
29771963 |
2018 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Female gender, history of heart failure or left ventricular ejection fraction <40%, and high levels (>1 mg/dL) of C-reactive protein (CRP) were independently associated with left atrial SEC/thrombosis.
|
27730663 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes.
|
28684396 |
2017 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
C-reactive protein levels reached a peak after 48 h. Patients with STEMI and signs of HF showed significantly higher peak CRP levels.
|
28883850 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed a cross-sectional analysis to investigate the relationships between inflammatory biomarkers [serum interleukin-6 (IL-6), C-reactive protein (hs-CRP) and serum amyloid A (SAA)] and median of 6 years follow-up for all-cause mortality and HF hospitalization among women with signs and symptoms of ischemia, non-obstructive CAD and preserved EF.
|
28542263 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After further adjustment for biomarkers (high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A<sub>2</sub> activity, high-sensitivity troponin I, and B-type natriuretic peptide), IL-6 remained significantly associated with the risk of major adverse cardiovascular events (adj HR Q4:Q1 1.43, 95% CI 1.09-1.88) and cardiovascular death or heart failure (adj HR 1.79, 95% CI 1.22-2.63).
|
29066436 |
2017 |